• If you are wondering whether Hims & Hers Health at around US$22.46 is a bargain or a value trap, the key is understanding what the current price actually reflects about the business.
• The stock has had a mixed run, with a 43.7% return over the past 30 days, set against a 9.7% decline over the past week and a 40.0% decline over the past year.
• Recent coverage has focused on Hims & Hers Health as a telehealth brand serving direct to consumer demand for health and wellness products, as well as on how competition and regulation shape the broader sector it operates in. This context helps explain why investors are reassessing both the opportunity and the risks implied by the share price moves.
• On Simply Wall St's valuation checks, Hims & Hers Health currently scores 3 out of 6. The next sections will walk through what different valuation methods say about that score and then introduce an approach that can give an even richer view of value.

Approach 1: Hims & Hers Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting future cash flows and discounting them back to their present value.

For Hims & Hers Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow is about $139.1 million. Analyst and extrapolated projections include free cash flow figures such as $113.0 million in 2026 and $442.1 million in 2030, with interim years stepping up between those points using analyst inputs for earlier years and Simply Wall St extrapolations for later years.

When these projected cash flows are discounted back and added together, the model arrives at an estimated intrinsic value of about $58.32 per share. Compared with the current share price of around $22.46, this implies the stock is about 61.5% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Hims & Hers Health is undervalued by 61.5%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: Hims & Hers Health Price vs Earnings

For a profitable business, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It helps you compare how the market prices the company against others that also generate earnings today, rather than relying only on long term forecasts.

In general, higher growth expectations or lower perceived risk can justify a higher P/E, while slower expected growth or higher risk usually means a lower P/E is more typical. That is why context matters when you look at any single multiple in isolation.

Hims & Hers Health currently trades on a P/E of 39.88x. This sits below the peer group average of 59.44x, but above the broader Healthcare industry average of 21.46x. Simply Wall St's Fair Ratio model, which estimates what a "normal" P/E might be for this company given its earnings growth profile, industry, profit margins, market value and risk factors, suggests a Fair Ratio of 19.89x.

Because the Fair Ratio is tailored to the company rather than just comparing against broad averages or selected peers, it can be a more focused guide to what investors are paying for its fundamentals.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Hims & Hers Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in as your way to attach a clear story to the numbers you see for Hims & Hers Health, including what you think is a fair value and how revenue, earnings and margins could evolve.

A Narrative on Simply Wall St is your statement of what you believe the company is really building, how that might translate into future financials, and therefore what you think the shares are worth. Instead of just accepting one DCF or P/E output, you connect the company story to a concrete forecast and then to a fair value estimate.

These Narratives live on the Hims & Hers Health Community page, where millions of investors share their views. They are designed to be easy to use, helping you quickly compare each Narrative fair value with the current price to decide whether the stock looks attractive, expensive or somewhere in between for your own approach.

Because Narratives on Simply Wall St update automatically when new information such as earnings, guidance or news is added to the platform, your chosen view on Hims & Hers Health does not sit still. It refreshes so you can see how the story and valuation move together over time.

For example, one Hims & Hers Health Narrative currently puts fair value at about US$173.02 based on an extensive multi year growth story and margin assumptions, while another sits closer to US$12.50 with lower margin and risk adjusted expectations. By comparing those with your own view you can choose which story, and which implied fair value, feels more realistic before you act on any buy or sell decision.

For Hims & Hers Health however we will make it really easy for you with previews of two leading Hims & Hers Health Narratives:

Fair value: about US$86.09 per share

Implied undervaluation vs last close: around 73.9%

Revenue growth assumption: 22%

• Views Hims & Hers Health as a platform for personalised, direct to consumer healthcare across multiple verticals rather than a single product or pill provider.
• Points to free cash flow generation, no debt, higher margins and growing personalisation as reasons the business model could scale efficiently.
• Flags regulatory, legal and execution risks, but still sees current pricing as attractive relative to the potential for a large, long term healthcare platform.

Fair value: about US$17.15 per share

Implied overvaluation vs last close: around 23.7%

Revenue growth assumption: very large

• Highlights strong reported revenue, subscriber numbers and telemedicine demand, but focuses on how much future growth and profitability are already built into expectations.
• Emphasises regulatory, competitive, operational and financial risks that could affect margins, customer growth and pricing power over time.
• Suggests that even with solid industry tailwinds, the current share price sits ahead of this narrative’s fair value estimate.

Do you think there's more to the story for Hims & Hers Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.